← Russell 3000 cross-section

NTRA Natera, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$48.7bn
Revenue TTM
$2.7bn
Net income TTM
$-192m
Free cash flow
$84m
Composite score
Sector rank
#244

Valuation

P / E
EV / EBITDA
EV / sales
18.0
FCF yield
0.17%
Earnings yield vs 10-yr
-5.12pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7.1%
EBITDA margin
-8.8%
ROE
-10.6%
ROIC
-15.2%
Revenue growth
37.8%

Insider activity, last 90 days

Net open-market
$-84.59m
Buyers
0
Sellers
11

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

This cloud-based distribution model results in lower revenues and gross profit per test than cases in which we process a test ourselves; however, because we do not incur the costs of processing the tests, our costs per test under this model are also lower. The percent of our revenues attributable to our U.S. direct sales force for the six months ended June 30, 2026 was 95% , a decrease compared to 96% for the six months ended June 30, 2025 . The percent of our revenues attributable to U.S. laboratory distribution partners for the six months ended June 30, 2026 was 3% , an increase compared to 2% from the same period in the prior year. …Natera, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →